Riverhead Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Riverhead Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$162K	Buy	5,886 +200	+4%	+$5.93K	0.01%	1205
2019 Q2	$188K	Hold	5,686	–	–	0.01%	1175
2019 Q1	$199K	Hold	5,686	–	–	0.01%	1125
2018 Q4	$189K	Hold	5,686	–	–	0.01%	1097
2018 Q3	$286K	Buy	5,686 +1,000	+21%	+$49.4K	0.01%	1029
2018 Q2	$281K	Hold	4,686	–	–	0.01%	925
2018 Q1	$215K	Buy	4,686 +200	+4%	+$8.35K	0.01%	1034
2017 Q4	$179K	Buy	4,486 +900	+25%	+$35.6K	0.01%	1130
2017 Q3	$143K	Buy	3,586 +524	+17%	+$22.7K	0.01%	1141
2017 Q2	$132K	Buy	3,062 +1,462	+91%	+$52K	0.01%	1106
2017 Q1	$50K	Buy	1,600 +200	+14%	+$5.36K	﹤0.01%	1263
2016 Q4	$35K	Hold	1,400	–	–	﹤0.01%	1325
2016 Q3	$35K	Sell	1,400 -778	-36%	-$17.6K	﹤0.01%	1282
2016 Q2	$58K	Sell	2,178 -6,966	-76%	-$124K	﹤0.01%	1294
2016 Q1	$140K	Sell	9,144 -356	-4%	-$4.64K	﹤0.01%	1312
2015 Q4	$128K	Buy	+9,500	New	+$147K	﹤0.01%	1306

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Riverhead Capital Management's SUPN Position: Q3 2019 in Review

Riverhead Capital Management increased its Supernus Pharmaceuticals (SUPN) stake by 3.5% in Q3 2019, buying an estimated $5.93K and bringing the position to 5,886 shares worth $162K. The position accounts for 0.01% of the portfolio, ranked #1205.

Riverhead Capital Management first reported a position in SUPN in Q4 2015 and has held it in 16 quarters since. The position peaked at $286K in Q3 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Riverhead Capital Management held 5,886 shares of Supernus Pharmaceuticals worth $162K as of Q3 2019.
Riverhead Capital Management bought 200 Supernus Pharmaceuticals shares in Q3 2019, an estimated $5.93K.
Supernus Pharmaceuticals made up 0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1205 holding.
Riverhead Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2015 and has held it in 16 quarters since.
Riverhead Capital Management's Supernus Pharmaceuticals position peaked at $286K in Q3 2018.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.